Gene Matrix Launches GeneMatrixAI™: A Revolutionary Leap in Genetic Reporting

"GeneMatrixAI delivers medical-grade genomic testing with 72-hour turnaround, transforming global healthcare with precision, speed, and scalability."

CHICAGO, IL, UNITED STATES, July 9, 2025 /EINPresswire.com/ -- Gene Matrix Inc., a leading biotech and precision medicine company, has unveiled GeneMatrixAI™, its groundbreaking artificial intelligence platform designed to transform the speed, accuracy, and accessibility of genetic testing across clinical and preventive care.

More than just software, GeneMatrixAI™ represents the future of diagnostics — combining cutting-edge genomics, real-time cloud analytics, and predictive algorithms to empower healthcare systems with actionable reports in under 72 hours.

“This isn’t just a reporting tool — it’s a clinical decision-making engine,” said Tarek Younis, CEO of Gene Matrix Inc. “GeneMatrixAI™ translates complex genomic data into clear, treatment-guiding insights for clinicians, patients, and health systems alike.”

🔍 Key Features of GeneMatrixAI™
🚀 72-Hour Turnaround: Results generated and delivered within three days of sample receipt

🔬 Fully Automated Interpretation: Based on global pharmacogenomic guidelines (FDA, CPIC, PharmGKB)

📊 AI-Powered Dashboards: Dynamic clinician dashboards with clinical summaries, medication alerts, and risk flags

📡 API Integration: Seamlessly connects to EMRs, lab systems, and healthcare networks

🛡️ GDPR & HIPAA Compliant: Designed with ISO 27001 and ISO 15189 architecture for global data security

🌍 A Global Solution, Built for Every Market
GeneMatrixAI™ is already powering diagnostics across Slovenia, Serbia, Mexico, Kazakhstan, and several other countries. Now, as it enters new markets like the United Kingdom, UAE, and Bosnia, it provides scalable infrastructure that can support tens of thousands of tests per month across pharmacogenomics, oncology, mental health, pediatric genomics, and preventive care.

📈 Transforming Healthcare with Predictive Precision
With adverse drug reactions costing healthcare systems billions annually and misdiagnoses delaying treatment for rare conditions, GeneMatrixAI™ delivers value beyond the lab:

40% reduction in ADR-related hospitalizations

70% faster diagnosis for rare disease patients

Up to 30% improvement in therapy response for psychiatric conditions

Millions in projected annual cost savings per national system

“GeneMatrixAI™ is not just an innovation — it’s a tool for health equity, accessibility, and sustainability,” said Lammy Shaheen, Director of International Operations. “We built it to scale across nations, empowering both large hospitals and remote clinics with the same diagnostic precision.”

🔗 The Road Ahead
Gene Matrix plans to roll out localized language support, multi-panel reporting, and AI-driven preventive analytics dashboards tailored for ministries of health and private insurers. Future updates will integrate machine learning models for longevity, oncology recurrence prediction, and population health mapping.

About Gene Matrix Inc
Gene Matrix is a US-based biotech and AI healthcare company delivering medical-grade genomic diagnostics to hospitals, governments, and providers worldwide. With a growing footprint in Europe, Central Asia, and the Middle East, the company specializes in plug-and-play lab setups, franchise integration, and AI-powered clinical platforms.

Tarek Younis
Gene Matrix LLC
+1 8473029668
email us here
Visit us on social media:
LinkedIn
Instagram
Facebook
TikTok

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.